Lupin Receives Approval from U.S. FDA for Chlorpromazine Hydrochloride Tablets USP
Lupin Receives Approval from U.S. FDA for Chlorpromazine Hydrochloride Tablets USP
Quality / GMP | 18/07/2023 | By Sudeep Soparkar | 527
Gland Pharma Limited - Conclusion of US FDA Inspection at Dundigal Facility, Hyderabad
Gland Pharma Limited - Conclusion of US FDA Inspection at Dundigal Facility, Hyderabad
Quality / GMP | 17/07/2023 | By Sudeep Soparkar | 860
Lupin Receives EIR from U.S. FDA for its Pithampur Unit-2 Manufacturing Facility
Lupin Receives EIR from U.S. FDA for its Pithampur Unit-2 Manufacturing Facility
Quality / GMP | 13/07/2023 | By Sudeep Soparkar | 750
USFDA inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad concludes with nil observations
Quality / GMP | 10/07/2023 | By Sudeep Soparkar | 1209
Zydus receives EIR from the USFDA for its SEZ 1 manufacturing facility at Pharmez, Ahmedabad
Zydus receives EIR from the USFDA for its SEZ 1 manufacturing facility at Pharmez, Ahmedabad
Quality / GMP | 06/07/2023 | By Sudeep Soparkar | 940
Quality / GMP | 06/07/2023 | By Sudeep Soparkar | 566
US FDA Inspection at Pashmylaram Facility, Hyderabad of Gland Pharma Ltd
US FDA Inspection at Pashmylaram Facility, Hyderabad of Gland Pharma Ltd
Quality / GMP | 28/06/2023 | By Sudeep Soparkar | 762
Ipca Laboratories Ltd receives 8 observations from USFDA for formulations facility at SEZ Indore, Pithampur
Quality / GMP | 26/06/2023 | By Sudeep Soparkar | 1552
Gufic receives approval from NMPA, China for Prilocaine API
Gufic receives approval from NMPA, China for Prilocaine API
Quality / GMP | 19/06/2023 | By Sudeep Soparkar | 477
NATCO receives final approval for Tipiracil Hydrochloride and Trifluridine for the US market
NATCO receives final approval for Tipiracil Hydrochloride and Trifluridine for the US market
Quality / GMP | 19/06/2023 | By Sudeep Soparkar | 770
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy